Hints and tips:
Related Special Reports
...While acknowledging that AstraZeneca has “a global reach, is in a high-paying sector, with a particularly well-regarded CEO at the helm,” ISS said that it remained concern by “the scale of the increase”....
...“There is a compensation issue at AstraZeneca,” Jain, a top-20 shareholder, told the Financial Times....
...AstraZeneca has a market capitalisation of £171bn....
...UK ministers are hoping to secure a major new vaccines investment by AstraZeneca with a possible state aid package worth tens of millions of pounds, in a deal that would deliver a big boost to Britain’s...
...“We have retained a team of professionals from B Riley Advisory Services (a division of B Riley Financial) to assist with managing through various operational challenges,” the memo said....
...AstraZeneca is withdrawing its Covid-19 jab, saying there is a “surplus of available updated vaccines” and that its product is no longer being manufactured or supplied....
...Unlike rivals Pfizer and BioNTech and Moderna, AstraZeneca initially adopted a non-profit model for its vaccine, selling it “at cost” as part of its agreement with Oxford, and the drug played a key role...
...than a decade....
...AstraZeneca has promised to increase its dividend by 7 per cent this year, ahead of a key shareholder vote on pay for its long-standing chief executive Pascal Soriot....
...AstraZeneca shareholders approved a potential £1.8mn pay rise for chief executive Pascal Soriot, despite a significant investor revolt against a pay increase advisers had called “excessive”....
...AstraZeneca was among the first companies this year to receive votes from shareholders on a proposed policy that sets out the incentive structure for the next three years....
...AstraZeneca has reported successful trial results for one of its top cancer drugs, in a boost to the drugmaker’s ambitions for its medication to be a treatment option for more than half of lung cancer patients...
...Soriot said on Thursday that AstraZeneca’s deal activity would continue but “at a slower pace”....
...The company will increase its footprint at a Cambridge biomedical site and build a vaccine manufacturing site in Speke in Liverpool....
...AstraZeneca is starting its next 10-year cycle from a very different place....
...The deal follows AstraZeneca’s $1bn acquisition of a French rare diseases start-up Amolyt last week....
...It follows AstraZeneca’s $1bn acquisition of a French rare diseases start-up Amolyt last week....
...Revenue was slightly ahead of analysts’ expectations, with oncology drugs making up more than a third of sales....
...If you diagnose it early, you can make a difference to this disease. These data reinforce that message,” said Susan Galbraith, executive vice-president of oncology R&D at AstraZeneca....
...AstraZeneca has a portfolio of well-established cancer drugs including lung cancer medicine Tagrisso, which had more than $5bn in revenues last year....
...AstraZeneca wrongfully dismissed a senior scientist working on one of its recently approved cancer drugs, a UK employment tribunal has found....
...Kingfisher, owner of the B&Q, Screwfix and Castorama DIY chains, has warned that profits will fall again this year, after a 25 per cent drop in the year to January....
...AstraZeneca is buying its first vaccine company in a deal worth up to $1.1bn, as it invests in the infectious disease unit it set up during the Covid-19 pandemic....
...For AstraZeneca, the expectation was always that its vaccine was a one-off endeavour, and the bubble had burst by the time its pledge to sell the jab at cost had expired....
International Edition